Literature DB >> 25672064

Sofosbuvir-ribavirin duo for chronic hepatitis C.

Basile Njei.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25672064      PMCID: PMC4821410     

Source DB:  PubMed          Journal:  Conn Med        ISSN: 0010-6178


× No keyword cloud information.
  7 in total

1.  A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints.

Authors:  Roger M Harbord; Matthias Egger; Jonathan A C Sterne
Journal:  Stat Med       Date:  2006-10-30       Impact factor: 2.373

Review 2.  Treatment failure with new hepatitis C drugs.

Authors:  Vincent Soriano; Eugenia Vispo; Eva Poveda; Pablo Labarga; Pablo Barreiro
Journal:  Expert Opin Pharmacother       Date:  2012-01-14       Impact factor: 3.889

3.  Meta-analysis in clinical trials.

Authors:  R DerSimonian; N Laird
Journal:  Control Clin Trials       Date:  1986-09

4.  Sofosbuvir for previously untreated chronic hepatitis C infection.

Authors:  Eric Lawitz; Alessandra Mangia; David Wyles; Maribel Rodriguez-Torres; Tarek Hassanein; Stuart C Gordon; Michael Schultz; Mitchell N Davis; Zeid Kayali; K Rajender Reddy; Ira M Jacobson; Kris V Kowdley; Lisa Nyberg; G Mani Subramanian; Robert H Hyland; Sarah Arterburn; Deyuan Jiang; John McNally; Diana Brainard; William T Symonds; John G McHutchison; Aasim M Sheikh; Zobair Younossi; Edward J Gane
Journal:  N Engl J Med       Date:  2013-04-23       Impact factor: 91.245

5.  Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options.

Authors:  Ira M Jacobson; Stuart C Gordon; Kris V Kowdley; Eric M Yoshida; Maribel Rodriguez-Torres; Mark S Sulkowski; Mitchell L Shiffman; Eric Lawitz; Gregory Everson; Michael Bennett; Eugene Schiff; M Tarek Al-Assi; G Mani Subramanian; Di An; Ming Lin; John McNally; Diana Brainard; William T Symonds; John G McHutchison; Keyur Patel; Jordan Feld; Stephen Pianko; David R Nelson
Journal:  N Engl J Med       Date:  2013-04-23       Impact factor: 91.245

6.  Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial.

Authors:  Anuoluwapo Osinusi; Eric G Meissner; Yu-Jin Lee; Dimitra Bon; Laura Heytens; Amy Nelson; Michael Sneller; Anita Kohli; Lisa Barrett; Michael Proschan; Eva Herrmann; Bhavana Shivakumar; Wenjuan Gu; Richard Kwan; Geb Teferi; Rohit Talwani; Rachel Silk; Colleen Kotb; Susan Wroblewski; Dawn Fishbein; Robin Dewar; Helene Highbarger; Xiao Zhang; David Kleiner; Brad J Wood; Jose Chavez; William T Symonds; Mani Subramanian; John McHutchison; Michael A Polis; Anthony S Fauci; Henry Masur; Shyamasundaran Kottilil
Journal:  JAMA       Date:  2013-08-28       Impact factor: 56.272

7.  Diagnosis, management, and treatment of hepatitis C: an update.

Authors:  Marc G Ghany; Doris B Strader; David L Thomas; Leonard B Seeff
Journal:  Hepatology       Date:  2009-04       Impact factor: 17.425

  7 in total
  2 in total

Review 1.  Direct-acting antivirals for chronic hepatitis C.

Authors:  Janus C Jakobsen; Emil Eik Nielsen; Joshua Feinberg; Kiran Kumar Katakam; Kristina Fobian; Goran Hauser; Goran Poropat; Snezana Djurisic; Karl Heinz Weiss; Milica Bjelakovic; Goran Bjelakovic; Sarah Louise Klingenberg; Jian Ping Liu; Dimitrinka Nikolova; Ronald L Koretz; Christian Gluud
Journal:  Cochrane Database Syst Rev       Date:  2017-09-18

Review 2.  Direct-acting antivirals for chronic hepatitis C.

Authors:  Janus C Jakobsen; Emil Eik Nielsen; Joshua Feinberg; Kiran Kumar Katakam; Kristina Fobian; Goran Hauser; Goran Poropat; Snezana Djurisic; Karl Heinz Weiss; Milica Bjelakovic; Goran Bjelakovic; Sarah Louise Klingenberg; Jian Ping Liu; Dimitrinka Nikolova; Ronald L Koretz; Christian Gluud
Journal:  Cochrane Database Syst Rev       Date:  2017-06-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.